Loading...
In a retrospective cohort study, investigators assessed the rate of adverse events associated with nebulized 3% hypertonic saline administered without bronchodilators in children younger than 2 years who were admitted to a children's hospital in Texas for bronchiolitis. Children with chronic lung disease, neuromuscular impairment, immunodeficiency, or congenital heart disease were excluded. Data were extracted from a database established as part of a quality improvement project on use of a bronchiolitis respiratory distress score. Respiratory therapists documented adverse events, broadly defined as any symptom thought to be related to treatment.
During the 3-month study period, 68 patients received 444 doses of hypertonic saline (mean number…